Cargando…

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer

Prostate cancer is the most frequently diagnosed non-cutaneous tumor of men in Western countries. While surgery is often successful for organ-confined prostate cancer, androgen ablation therapy is the primary treatment for metastatic prostate cancer. However, this therapy is associated with several...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chuu, Chih-Pin, Kokontis, John M, Hiipakka, Richard A, Fukuchi, Junichi, Lin, Hui-Ping, Lin, Ching-Yu, Huo, Chiech, Su, Liang-Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3170584/ https://www.ncbi.nlm.nih.gov/pubmed/21859492 http://dx.doi.org/10.1186/1423-0127-18-63

Ejemplares similares

Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
por: Kokontis, John M., et al.
Publicado: (2014)

PRPF6 promotes androgen receptor/androgen receptor-variant 7 actions in castration-resistant prostate cancer cells
por: Liu, Wei, et al.
Publicado: (2021)

Caffeic acid phenethyl ester suppresses androgen receptor signaling and stability via inhibition of phosphorylation on Ser81 and Ser213
por: Kuo, Ying-Yu, et al.
Publicado: (2019)

Elevation of androgen receptor promotes prostate cancer metastasis by induction of epithelial‐mesenchymal transition and reduction of KAT5
por: Lin, Ching‐Yu, et al.
Publicado: (2018)

Persistent androgen receptor addiction in castration-resistant prostate cancer
por: Schweizer, Michael T., et al.
Publicado: (2015)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
por: Feng, Qin, et al.
Publicado: (2019)

Ratio of the expression levels of androgen receptor splice variant 7 to androgen receptor in castration refractory prostate cancer
por: Sekine, Yoshitaka, et al.
Publicado: (2021)

The androgen receptor can signal through Wnt/β-Catenin in prostate cancer cells as an adaptation mechanism to castration levels of androgens
por: Schweizer, Liang, et al.
Publicado: (2008)

Dominant-Negative Androgen Receptor Inhibition of Intracrine Androgen-Dependent Growth of Castration-Recurrent Prostate Cancer
por: Titus, Mark A., et al.
Publicado: (2012)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

New classification may assist the development of targeted therapies for treatment-refractory castration-resistant prostate cancer
por: Lin, Ching-Yu, et al.
Publicado: (2020)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
por: Ban, Fuqiang, et al.
Publicado: (2021)

Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

Orphan nuclear receptor TLX contributes to androgen insensitivity in castration-resistant prostate cancer via its repression of androgen receptor transcription
por: Jia, Lin, et al.
Publicado: (2018)

Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
por: Perner, Sven, et al.
Publicado: (2015)

Inhibiting androgen receptor nuclear entry in castration-resistant prostate cancer
por: Pollock, Julie A., et al.
Publicado: (2016)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Recent Discoveries in the Androgen Receptor Pathway in Castration-Resistant Prostate Cancer
por: Obinata, Daisuke, et al.
Publicado: (2020)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
por: Yamada, Shigetomo, et al.
Publicado: (2022)

Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer
por: Hussain, Arif, et al.
Publicado: (2020)

The Androgen Receptor and Its Crosstalk With the Src Kinase During Castrate-Resistant Prostate Cancer Progression
por: Gao, Lin, et al.
Publicado: (2022)

Androgen Receptor Variants Occur Frequently in Castration Resistant Prostate Cancer Metastases
por: Zhang, Xiaotun, et al.
Publicado: (2011)

Experimental Evidence of Persistent Androgen-Receptor-Dependency in Castration-Resistant Prostate Cancer
por: Kobayashi, Takashi, et al.
Publicado: (2013)

Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
por: Lallous, Nada, et al.
Publicado: (2013)

Androgen receptor targeted therapies in castration‐resistant prostate cancer: Bench to clinic
por: Imamura, Yusuke, et al.
Publicado: (2016)

Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer
por: Mout, Lisanne, et al.
Publicado: (2020)

Androgen Receptor Targeted Therapy + Radiotherapy in Metastatic Castration Resistant Prostate Cancer
por: Massaro, Maria, et al.
Publicado: (2021)

Androgen receptor signaling and spatial chromatin organization in castration-resistant prostate cancer
por: Zhou, Tianyi, et al.
Publicado: (2022)

Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer
por: Hung, Chiu-Lien, et al.
Publicado: (2023)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
por: Pak, Sahyun, et al.
Publicado: (2022)

Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer
por: Batth, Izhar, et al.
Publicado: (2016)

Abiraterone switches castration‐resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling
por: Moll, J. Matthijs, et al.
Publicado: (2022)

Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer
por: Gui, Bin, et al.
Publicado: (2017)

Correction: Androgen Suppresses the Proliferation of Androgen Receptor-Positive Castration-Resistant Prostate Cancer Cells via Inhibition of Cdk2, CyclinA, and Skp2
Publicado: (2014)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

The expression of AURKA is androgen regulated in castration-resistant prostate cancer
por: Kivinummi, Kati, et al.
Publicado: (2017)

Gene amplification of YB‐1 in castration‐resistant prostate cancer in association with aberrant androgen receptor expression
por: Shiota, Masaki, et al.
Publicado: (2020)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Sox2 Is an Androgen Receptor-Repressed Gene That Promotes Castration-Resistant Prostate Cancer
por: Kregel, Steven, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_k483ng2ttbvu25dg5sg0phfdds